Trial Profile
Lengthening Adalimumab Dosing Interval in IBD patients in long term remission, the LADI study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Mar 2015
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms LADI
- 02 Jul 2014 New trial record